The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The RSV vaccine isn't needed annually like the flu vaccine ... headache and joint pain. In the combined clinical trials of ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

mRESVIA is a RSV vaccine available in a pre-filled syringe ... Health Canada's approval is based on data from the Phase 3 ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Clover Biopharmaceuticals Ltd. (HK:2197) has released an update. Clover Biopharmaceuticals announced promising results from its Phase I trial ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

RSV is a virus that can cause lung and respiratory ... In the combined clinical trials of the vaccine, 20 out of more than 38,000 people who received the shot reported an abnormal heart rate ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to ...